Aseptic Packaging For The Pharmaceutical Companies – Top Company List [Updated] | Global Growth Insights

Aseptic packaging for pharmaceuticals refers to the technique of filling and sealing sterile pharmaceutical products under sterile conditions into sterilized containers, maintaining product integrity and eliminating contamination risks. This form of packaging is critical in extending product shelf life, ensuring patient safety, and meeting regulatory standards in drug manufacturing and biologics.

The demand for aseptic packaging is surging due to the rising production of biologics, vaccines, pre-filled syringes, and other parenteral formulations. With the global pharmaceutical industry rapidly expanding and facing stricter regulations, aseptic packaging solutions are evolving to meet complex demands in drug delivery and cold-chain integrity.

In 2025, more than 12,000 global pharmaceutical manufacturing sites are utilizing some form of aseptic packaging technology. Of these, around 3,800 sites are fully compliant with international aseptic standards such as EU Annex 1 and U.S. FDA cGMP.

Aseptic Packaging for the Pharmaceutical Market was valued at USD 8.86 billion in 2023 and is expected to reach USD 9.67 billion in 2024, growing significantly to USD 19.41 billion by 2032, at a CAGR of 9.1% during the forecast period from 2024 to 2032.

USA: Growing Aseptic Packaging Market for Pharmaceuticals

The U.S. pharmaceutical aseptic packaging segment has shown robust performance as of 2025:

• Over 920 sterile injectable drug products are currently manufactured in aseptic environments across the U.S.
• More than 340 pharmaceutical companies in the U.S. operate sterile filling lines or aseptic processing units.
• 420+ aseptic cleanrooms and sterile lines were active in 2024, with over 65 new installations underway in 2025.
• Major growth is seen in packaging for mRNA vaccines, biosimilars, and oncology injectables.
• States like California, New Jersey, and Massachusetts lead with high-output facilities and packaging innovations.
• $2.4 billion in funding was allocated in 2024 across state-level pharmaceutical packaging infrastructure development.

Regional Market Share & Insights

Europe:

• Over 1,200 pharmaceutical manufacturing facilities with aseptic processing capabilities.
• Germany, Switzerland, and Italy account for 67% of the region's aseptic packaging capacity.
• Around 280 new aseptic filling and sealing lines were commissioned in 2024.
• Regulatory audits and compliance checks increased by 22% YoY to enhance sterility assurance.

Asia-Pacific:

• Home to over 1,500 pharmaceutical and biologics companies utilizing aseptic packaging lines.
• India and China saw a combined 33% increase in sterile injectable drug production from 2023 to 2025.
• Japan alone reported 190+ installations of robotic aseptic systems since 2022.
• $1.1 billion in government grants supported aseptic line modernization in the region.

Latin America:

• Brazil and Mexico are the largest markets, with over 210 active aseptic manufacturing units.
• More than 80 new aseptic packaging lines were installed between 2023 and 2025.
• The region invested $320 million into localized packaging hubs with a focus on pediatric and vaccine drugs.

Middle East & Africa:

• The region has fewer than 100 fully compliant aseptic packaging facilities, but growth is accelerating.
• Saudi Arabia and UAE invested $145 million combined into 30+ packaging centers.
• 17 cross-border tech transfer agreements were signed with EU and U.S. aseptic solution providers.

Global Growth Insights unveils the top List Global Aseptic Packaging For The Pharmaceutical Companies:

Amcor Plc

• Strategy: Focuses on lightweight, recyclable, and high-barrier packaging materials for pharma and biologics.
• Key Products: Formpack blister packs, Flexibles for IV bags, and pharmaceutical sachets.
• Facilities: Operates in over 40 countries with more than 200 production sites globally.

Gerresheimer AG

• Strategy: Expanding portfolio in biologics and combination products through smart packaging and injection systems.
• Key Products: Gx RTF vials, plastic containers, prefilled syringes, and customized drug delivery devices.
• In 2024, produced over 3.5 billion glass vials and 1.2 billion prefilled syringes.

Oliver-Tolas Healthcare Packaging

• Strategy: Specializes in sterile barrier systems, targeting biologics, diagnostics, and combination devices.
• Key Products: CleanCut cards, pouches, and thermoform trays.
• Serves more than 100 global pharma customers with 10 regional plants.

SCHOTT AG

• Strategy: Innovating in prefillable glass solutions with enhanced break resistance and safety for biologics.
• Key Products: SCHOTT TopPac polymer syringes, adaptiQ ready-to-use vials, and prefillable cartridges.
• Annually produces over 12 billion pharmaceutical containers.

Bosch Packaging Technology (now Syntegon Technology)

• Strategy: Integrating AI, robotics, and sustainability in sterile fill-finish lines.
• Key Products: Aseptic vial and syringe filling machines, barrier systems, and isolator technology.
• Has installed over 7,000 packaging machines worldwide by 2025.

Catalent Inc.

• Strategy: Strengthening CDMO capabilities across oral, biologics, and inhalation drugs with end-to-end sterile packaging.
• Key Products: Blow-Fill-Seal units, OptiDose softgel capsules, and injectable delivery formats.
• In 2024, Catalent packaged over 4.8 billion doses globally.

WestRock Company

• Strategy: Leading in secondary packaging with smart labeling and sustainability as core pillars.
• Key Products: Folding cartons, serialization packaging, and smart pill dispensers.
• Operates over 300 manufacturing facilities across the Americas and Europe.

West Pharmaceutical Services Inc.

• Strategy: Developing containment and delivery systems tailored for injectable biologics and vaccines.
• Key Products: NovaPure components, SmartDose delivery systems, and prefilled syringe seals.
• Delivers over 45 billion components annually for injectable drug packaging.

Montagu Private Equity LLP

• Strategy: Investment in niche contract packaging firms and biologics packaging services.
• Key Products: Focus varies by portfolio company; commonly includes sterile packaging, biologics filling.
• Portfolio companies reported handling over 200 million sterile units annually.

BD Medical

• Strategy: Global expansion in prefilled delivery systems and infection prevention platforms.
• Key Products: BD Hypak syringes, BD Neopak glass barrels, BD Sterifill advance system.
• Manufactures more than 7 billion drug delivery devices annually across 50+ sites.

Regional Opportunities

• North America: Growth in CDMO partnerships, expansion in injectable drug packaging, and mRNA vaccine packaging solutions.
• Europe: Smart packaging technology for tracking, sustainability-focused container innovation.
• Asia-Pacific: Outsourced sterile manufacturing, government incentives, and biologics innovation.
• Latin America: Boost in local production and public-private collaborations.
• Middle East & Africa: Strategic entry points for export-led aseptic packaging services.

Conclusion: The Future of Aseptic Pharmaceutical Packaging

As of 2025, aseptic packaging has become central to pharmaceutical integrity and efficiency. The industry is shaped by innovation in biologics, the explosion in vaccine demand, and stringent quality mandates.

Companies are investing in single-use systems, robotics, and contamination control technologies to meet the evolving needs. Multinationals like Amcor, BD Medical, and Catalent continue to expand production footprints and service models, reinforcing global supply chain resilience.

With every region intensifying its focus on sterile safety, the aseptic pharmaceutical packaging market is poised for resilient, high-technology-driven growth over the next decade.